Russia says registers third coronavirus vaccine

AFP
Moscow, Russia Published: Feb 20, 2021, 02:35 PM(IST)

Representative image Photograph:( Reuters )

Story highlights

Russia was the first country to register a vaccine against COVID-19 in August ahead of clinical trials

Moscow announced Saturday it had registered its third vaccine against the coronavirus and promised to introduce the jab to the Russian population by March.

Russia was the first country to register a vaccine against COVID-19 in August ahead of clinical trials, and the Sputnik V jab has been authorised in more than two dozen countries around the world.

"Today we note that a third vaccine, CoviVac, has been registered," Prime Minister Mikhail Mishustin said at a government meeting broadcast on state television.

Also read| After snap lockdown, New Zealand begins vaccine programme

"And already in mid-March, the first 120,000 doses will be distributed within the civilian circulation," he told the cabinet.

First greeted with scepticism, the effectiveness of Sputnik V was confirmed by the Lancet medical journal earlier this month.

Moscow relied on the nationwide rollout of the vaccine to stave off the impact of the second wave of infections that battered the country late last year.

Also read| Argentina's health minister resigns over VIP treatment to get Covid-19 vaccines

But mortality data released recently revealed that Russia's death rate was still one of the highest in the world.

President Vladimir Putin announced in October that the country had registered its second vaccine, EpiVacCorona, which health officials had said would enter mass production this month.

Mishustin said Saturday that Russia had produced 10 million doses of Sputnik and 80,000 batches of the EpiVacCorona vaccine developed by the Siberian Vektor laboratory.

Also read| White House working with Facebook and Twitter to tackle anti-vaxxers

With the introduction of the third jab Saturday, the prime minister said that: "Today Russia is the only country in which there are already three vaccines for the prevention of Covid infection."

CoviVac was produced by the state-run Chumakov Centre based in Moscow, which employed a different method of development from Sputnik and EpiVacCorona, using an inactive virus.

The vaccine is due to complete final stage clinical trial with 3,000 participants in March and has so far been recommended for people below the age of 60.

Read in App